v3.26.3
Condensed Consolidated Statements of Stockholders’ Equity (unaudited) - USD ($)
$ in Thousands
Total
Total Stockholders’ Equity attributable to Privia Health Group, Inc.
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Non-controlling Interest
Beginning balance (in shares) at Dec. 31, 2024     120,309,346      
Beginning balance at Dec. 31, 2024 $ 683,447 $ 635,183 $ 1,203 $ 813,209 $ (179,229) $ 48,264
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock upon exercise of stock options and vesting of restricted stock units (in shares)     1,081,968      
Issuance of common stock upon exercise of stock options and vesting of restricted stock units 2,243 2,243 $ 11 2,232    
Stock-based compensation expense 17,790 17,790   17,790    
Net income 6,046 4,220     4,220 1,826
Ending balance (in shares) at Mar. 31, 2025     121,391,314      
Ending balance at Mar. 31, 2025 709,526 659,436 $ 1,214 833,231 (175,009) 50,090
Beginning balance (in shares) at Dec. 31, 2024     120,309,346      
Beginning balance at Dec. 31, 2024 683,447 635,183 $ 1,203 813,209 (179,229) 48,264
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 19,141          
Ending balance (in shares) at Sep. 30, 2025     122,867,531      
Ending balance at Sep. 30, 2025 762,761 709,124 $ 1,229 873,356 (165,461) 53,637
Beginning balance (in shares) at Mar. 31, 2025     121,391,314      
Beginning balance at Mar. 31, 2025 709,526 659,436 $ 1,214 833,231 (175,009) 50,090
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock upon exercise of stock options and vesting of restricted stock units (in shares)     1,281,940      
Issuance of common stock upon exercise of stock options and vesting of restricted stock units 1,883 1,883 $ 13 1,870    
Stock-based compensation expense 18,849 18,849   18,849    
Net income 3,288 2,687     2,687 601
Ending balance (in shares) at Jun. 30, 2025     122,673,254      
Ending balance at Jun. 30, 2025 733,546 682,855 $ 1,227 853,950 (172,322) 50,691
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock upon exercise of stock options and vesting of restricted stock units (in shares)     194,277      
Issuance of common stock upon exercise of stock options and vesting of restricted stock units 431 431 $ 2 429    
Stock-based compensation expense 18,977 18,977   18,977    
Net income 9,807 6,861     6,861 2,946
Ending balance (in shares) at Sep. 30, 2025     122,867,531      
Ending balance at Sep. 30, 2025 $ 762,761 709,124 $ 1,229 873,356 (165,461) 53,637
Beginning balance (in shares) at Dec. 31, 2025 123,604,576   123,604,576      
Beginning balance at Dec. 31, 2025 $ 790,943 737,217 $ 1,236 892,291 (156,310) 53,726
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock upon exercise of stock options and vesting of restricted stock units (in shares)     2,084,429      
Issuance of common stock upon exercise of stock options and vesting of restricted stock units 774 774 $ 21 753    
Stock-based compensation expense 21,921 21,921   21,921    
Repurchase of non-controlling interest (11,444) (9,917)   (9,917)   (1,527)
Net income 3,710 3,064     3,064 646
Ending balance (in shares) at Mar. 31, 2026     125,689,005      
Ending balance at Mar. 31, 2026 $ 805,904 753,059 $ 1,257 905,048 (153,246) 52,845
Beginning balance (in shares) at Dec. 31, 2025 123,604,576   123,604,576      
Beginning balance at Dec. 31, 2025 $ 790,943 737,217 $ 1,236 892,291 (156,310) 53,726
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income $ 28,038          
Ending balance (in shares) at Sep. 30, 2026 127,767,886   127,767,886      
Ending balance at Sep. 30, 2026 $ 872,914 815,716 $ 1,277 945,150 (130,711) 57,198
Beginning balance (in shares) at Mar. 31, 2026     125,689,005      
Beginning balance at Mar. 31, 2026 805,904 753,059 $ 1,257 905,048 (153,246) 52,845
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock upon exercise of stock options and vesting of restricted stock units (in shares)     600,978      
Issuance of common stock upon exercise of stock options and vesting of restricted stock units 826 826 $ 6 820    
Stock-based compensation expense 19,396 19,396   19,396    
Contributed non-controlling interest 2,213         2,213
Net income 9,734 9,048     9,048 686
Ending balance (in shares) at Jun. 30, 2026     126,289,983      
Ending balance at Jun. 30, 2026 838,073 782,329 $ 1,263 925,264 (144,198) 55,744
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock upon exercise of stock options and vesting of restricted stock units (in shares)     1,477,903      
Issuance of common stock upon exercise of stock options and vesting of restricted stock units 5,868 5,868 $ 14 5,854    
Stock-based compensation expense 14,032 14,032   14,032    
Contributed non-controlling interest 347         347
Net income $ 14,594 13,487     13,487 1,107
Ending balance (in shares) at Sep. 30, 2026 127,767,886   127,767,886      
Ending balance at Sep. 30, 2026 $ 872,914 $ 815,716 $ 1,277 $ 945,150 $ (130,711) $ 57,198